Tempest Therapeutics Inc. (TPST)
NASDAQ (CM) NASDAQ (CM) Primary 
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
Tempest jumps after EMA grants orphan drug status to its liver cancer candidate, amezalpat, based on positive study data.
TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up
Tempest aims to explore strategic alternatives for advancing pipeline studies that maximize shareholder value. Stock rises in after-hours trading.
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?
Tempest Therapeutics Inc. TPST stock is trading higher on Thursday, with a strong session volume of over 23 million as per data from Benzinga Pro.
What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?
Shares of Tempest Therapeutics Inc TPST are trading lower on Thursday, with a session volume of 21 million as per data from Benzinga Pro.
Why Is Tempest Therapeutics (TPST) Stock Up 45% Today?
Tempest Therapeutics (NASDAQ: TPST ) stock is heading higher on Thursday after the clinical-stage oncology company announced plans to show off new study data. Tempest Therapeutics will be holding a conference call at 8:30 a.m.
